Table 2

Post PCI characteristics at 30, 180, and 360 days from index PCI
30 days after PCI No psoriasis Mild psoriasis Severe psoriasis p–value
n= 49,696 n=1027 n=309
Male (%) 35,632 (72.7) 737 (72.8) 192 (62.1) 0.007
Female (%) 14,064 (28.3) 290 (28.2) 117 (37.9)
Primary PCI (%) 14,451 (29.1) 268 (26.1) 90 (29.1) 0.17
Treatment (%)
  Beta-blocker 38,916 (78.3) 772 (75.2) 230 (74.4) 0.005
  ACE inhibitor/ARB 25,032 (50.4) 509 (49.6) 167 (54.1) 0.54
  Statin 42,844 (86.2) 896 (86.3) 245 (79.3) 0.049
  Platelet inhibitor 47,949 (96.5) 991 (96.5) 285 (92.2) 0.003
  Dual anti-platelet inhibition 45,901 (92.4) 946 (92.1) 273 (88.4) 0.029
  Loop diuretic 9812 (19.7) 201 (19.6) 71 (23.0) 0.34
  Spironolactone 2852 (5.7) 53 (5.2) 23 (7.4) 0.67
  Vitamin K antagonist 2904 (5.8) 58 (5.7) 18 (5.8) 0.85
  Glucose-lowering medication 5586 (11.2) 112 (10.9) 52 (16.8) 0.039
  NSAID 1349 (2.7) 40 (3.9) 34 (11.0) 0.002
180 days after PCI No psoriasis Mild psoriasis Severe psoriasis p–value
n= 46,126 n=955 n=279
  Beta-blocker 36,431 (78.9) 727 (76.1) 212 (76.0) 0.05
  ACE inhibitor/ARB 23,324 (50.6) 484 (50.7) 153 (54.8) 0.36
  Statin 40,140 (87.0) 842 (88.2) 226 (81.0) 0.007
  Platelet inhibitor 44,696 (96.9) 927 (97.1) 260 (93.2) 0.002
  Dual anti-platelet inhibition 42,822 (92.8) 889 (93.1) 249 (89.3) 0.07
  Loop diuretic 8968 (19.4) 188 (19.7) 62 (22.2) 0.50
360 days after PCI No psoriasis Mild psoriasis Severe psoriasis p–value
n= 42,188 n=860 n=257
  Beta-blocker 33,507 (79.4) 665 (77.3) 195 (75.9) 0.124
  ACE inhibitor/ARB 21,389 (50.7) 430 (50.0) 140 (54.5) 0.44
  Statin 36,918 (87.5) 769 (89.4) 210 (81.7) 0.005
  Platelet inhibitor 40,985 (97.2) 840 (97.7) 239 (93.0) <0.001
  Dual anti-platelet inhibition 39,318 (93.2) 811 (94.3) 228 (88.7) 228 (88.7)
  Loop diuretic 8055 (19.1) 161 (18.7) 52 (20.3) 0.86

PCI: percutaneous coronary intervention; ACE: angiotensin-converting enzyme inhibitor; ARB: angiotensin 2 receptor blocker; NSAID: Non-steroid anti inflammatory drug.

Ahlehoff et al.

Ahlehoff et al. BMC Cardiovascular Disorders 2012 12:79   doi:10.1186/1471-2261-12-79

Open Data